Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes

D Chrysis, E M Ritzen and L Sävendahl

Department of Woman and Child Health, Pediatric Endocrine Unit, Astrid Lindgren Children’s Hospital, Karolinska Institute, SE-171 76 Stockholm, Sweden

(Requests for offprints should be addressed to D Chrysis; Email: Dionisios.Chrysis@kbh.ki.se)

Abstract

Glucocorticoids cause significant growth retardation in mammals and humans and decreased proliferation of chondrocytes has been considered as the main local mechanism. Death by apoptosis is an important regulator of homeostasis in multicellular organisms. Here we chose to study the role of apoptosis in growth retardation caused by glucocorticoid treatment. We treated 7-week-old male rats with dexamethasone (5 mg/kg/day) for 7 days. Apoptosis was studied in tibiae growth plates by the TUNEL method. Immunoreactivity for parathyroid hormone-related peptide (PTHrP), caspase-3, and the anti-apoptotic proteins Bcl-2 and Bcl-x was also studied. Apoptosis was mainly localized in terminal hypertrophic chondrocytes (THCs) in both control and dexamethasone-treated animals. Dexamethasone caused an increase in apoptosis which was fourfold in THCs (2·45 ± 0·12 vs 0·62 ± 0·09 apoptotic cells/mm growth plate, \( P<0·001 \)), and 18-fold in proliferative chondrocytes (0·18 ± 0·04 vs 0·01 ± 0·007 apoptotic cells/mm growth plate, \( P<0·001 \)). Increased apoptosis after dexamethasone treatment was accompanied by increased immunoreactivity for caspase-3 and decreased immunoreactivity for the anti-apoptotic proteins Bcl-2 and Bcl-x, which further supports our apoptosis results. Dexamethasone also decreased the immunoreactivity for PTHrP, suggesting a role in the mechanism by which glucocorticoids induce apoptosis in the growth plate. We conclude that apoptosis is one mechanism involved in growth retardation induced by glucocorticoids. Premature loss of resting/proliferative chondrocytes by apoptosis could contribute to incomplete catch-up seen after prolonged glucocorticoid treatment. Journal of Endocrinology (2003) 176, 331–337

Introduction

Impaired longitudinal growth is a well-established side effect of glucocorticoid treatment in humans and animals (Altman et al. 1992, Allen 1996). The decreased growth is accompanied by morphological changes in the growth plate. It becomes thinner (Altman et al. 1992, An nefeld 1992), which has been attributed to decreased proliferation of the chondrocytes (Kember & Walker 1971, An nefeld 1992). Glucocorticoids also alter the synthetic capability of chondrocytes with consequent alterations in the cartilage matrix (An nefeld 1992) and enhanced formation of electron-dense, dark-staining degenerate-appearing chondrocytes (Dearden et al. 1986).

Multiple mechanisms, both endocrine and paracrine, have been implicated as the cause of growth retardation caused by glucocorticoids. Alterations of the growth hormone/insulin–like growth factor–I (GH/IGF-I) axis at multiple levels (Allen 1996, Mehls et al. 2001) have been described. In addition to systemic effects, glucocorticoids also have local effects on the growth plate, the structure responsible for longitudinal bone growth (Baron et al. 1994). Decreased proliferation of epiphyseal chondrocytes and alterations in the local production of GH/IGF-I have been reported as possible mechanisms (Kember & Walker 1971, An nefeld 1992, Mehls et al. 2001).

Apoptosis acts as an important regulator of cell and tissue homeostasis by eliminating cells through a genetically programmed cell death. It has been suggested that apoptosis plays a role in growth plate homeostasis during development (Chrysis et al. 2002) and that apoptosis is the fate of the terminal hypertrophic chondrocytes (Franum & Wilsman 1987, Gibson et al. 1995). Furthermore, strong evidence that apoptosis is a regulator of growth plate homeostasis comes from in vivo experiments. As an example, mice with targeted disruptions of both alleles for the anti-apoptotic protein Bcl-2 have short limbs and accelerated ossification of their growth plates (Amling et al. 1997). In addition, two chondrodysplastic conditions (parathyroid hormone-related peptide (PTHrP) knock-out mice and activating mutations of the fibroblast growth factor–3 (FGFR–3)) are associated with increased apoptosis of the growth plate chondrocytes (Amizuka et al. 1994, Leggeai–Mallet et al. 1998).

In a multicellular organism or tissue, growth is accomplished when cell proliferation exceeds cell death.
Materials and Methods

Animals and sample preparation

After approval by the local ethical committee, 7-week-old male Sprague Dawley rats (B&K Universal, Sollentuna, Sweden) were housed in our animal care facility under a 12-h light, 12-h darkness schedule; food pellets were available ad libitum. After an adaptation period, 5 animals received dexamethasone (5 mg/kg body weight, s.c.) for 7 days, whereas the control group of 5 animals received vehicle only. Tibiae were removed and the upper part was fixed in 4% formaldehyde in 0.1 M phosphate buffer, pH 7.3, for 18 h at 4 °C. After fixation, specimens were decalcified in 5% EDTA and were then paraffin embedded. Sections, 5 µm thick, were cut longitudinally and mounted on histological glass slides (Superfrost +/+; Menzel-Gløeser, Braunschweig, Germany). On each slide, two sections were mounted, one from each group, so that all samples were treated under the same conditions during TUNEL and immunohistochemistry. Slides were dried at 37 °C overnight.

Determination of growth rate

For the determination of growth rate, the fluorescent marker calcine was administered i.p. as a single injection (10 mg/kg) at the start of a separate experiment which included 6 animals divided into two groups of 3 animals each. One group received vehicle during the 7 days of the experiment, whereas the other group received dexamethasone. Proximal tibiae were prepared as described above, non-decalcified tissues were embedded in methylmethacrylate blocks and 5 µm thick sections were cut longitudinally. The distance between the proximal borders of the calcine and the chondro-osseous junction of the growth plate was measured; this corresponds to the growth accomplished during 7 days.

Detection of apoptosis

Apopotic cells in the growth plates were identified by terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP nick end labeling (TUNEL), according to the manufacturer’s instructions (TdT-FragEL kit; Oncogene Research Products, Boston, MA, USA) with slight modifications (Chrysis et al. 2002): deparaffinized and rehydrated sections were treated with proteinase K (20 mcg/ml) at 37 °C for 10 min instead of 20 min. Treatment of sections with DNase labeled all cells, whereas sections treated with distilled water instead of TdT were negative. At least 5 sections from each animal, 25 µm apart (to avoid counting the same cells twice) were used to determine the number of apoptotic cells. The number of apoptotic chondrocytes was counted in the growth plate. Only cells in closed lacunae were counted and were expressed as their number per mm length of the chondro-osseous junction. The length of the chondro-osseous junction from each section was measured by the Image-Pro image analysis system (Media Cybernetics, Silver Spring, MD, USA).

Immunohistochemistry

The rabbit caspase-3 polyclonal antibody was purchased from Santa Cruz Biotechnology Inc. (1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), the Bcl-2 rabbit polyclonal antibody was from Upstate Biotechnology (1:600; Upstate Biotechnology, Lake Placid, NY, USA), and the rabbit polyclonal Bcl-x antibody was from Transduction Laboratories (1:500; Becton Dickinson AB, Stockholm, Sweden). For the immunodetection of PTHrP and a rabbit polyclonal antibody raised against amino acids 34–53 of human PTHrP was used (1:80; Oncogene Science, Cambridge, MA, USA). Control experiments were carried out with omission of the primary antibodies, incubation with non-specific rabbit IgG and competition of the primary antibody with corresponding peptide when available (PTHrP).

Sections were dewaxed in xylene and rehydrated in graded alcohol baths. Antigen retrieval was performed in 0.01 M citrate buffer (pH 6.0) at 95–98 °C for 20 min (for caspase-3 only) or with neuraminidase digestion for PTHrP (0.025 U/ml neuraminidase for 50 min at room temperature). Immunohistochemistry was carried out as previously described (Chrysis et al. 2002). Biotinylated goat anti-rabbit IgG (1:1000) was purchased from Jackson Immunoresearch Lab. (West Grove, PA, USA).
Avidin-conjugated peroxidase was purchased from Vector Laboratories (Burlingame, CA, USA), and a DAB-kit which generates a brown color for the detection of peroxidase activity was from Vector Laboratories. Digital microphotographs were captured by a Nikon Eclipse 800 microscope (Nikon, Bergström Instruments, Stockholm, Sweden) equipped with a Hamamatsu Orca IIIH CCD camera (Hamamatsu Inc, Stockholm, Sweden).

Immunopositive chondrocytes were detected by automatic thresholding using an image analysis system (Image-Pro; Media Cybernetics). For each antibody, at least 300 cells were analyzed in two separate sections of each specimen. Immunopositive cells are expressed as a percentage of the total number of cells analyzed in the proliferative and hypertropic zones respectively. For each antibody, all slides were processed in parallel in order for comparisons to be valid.

**Statistical analysis**

Results are expressed as means ± s.e. Differences between groups were tested by Student’s *t*-test. *P*<0·05 was considered significant.

**Results**

**Body weight and growth rate**

Before treatment was initiated, body weight was similar in the control (199·6 ± 4·6 g) and in the dexamethasone-treated (197·0 ± 2·5 g) group of animals. When killed after 7 days of treatment, body weight was increased by 32% in the control group (263·1 ± 5·0 g), whereas the dexamethasone group had lost 23% of the initial body weight (152·3 ± 2·9 g, *P*<0·001 vs control). Growth rate over the 7-day period of treatment was significantly higher in controls compared with dexamethasone-treated animals (207 ± 14 µm/day and 68 ± 5 µm/day respectively, *P*<0·001).

**Apoptosis**

Seven days of treatment with dexamethasone increased the number of apoptotic chondrocytes in all layers of the growth plate (Fig. 1). In both control and dexamethasone-treated animals most of the apoptotic chondrocytes were THCs. Compared with controls, dexamethasone caused a fourfold increase in apoptosis in THCs (2·45 ± 0·12 vs 0·62 ± 0·09 apoptotic cells/mm growth plate, *P*<0·001). Apoptotic proliferative chondrocytes were rare in sections from control animals and only occasional apoptotic cells were observed in a few sections. In contrast, sections from dexamethasone-treated animals regularly had some apoptotic proliferative chondrocytes, mainly early proliferative (Fig. 1), resulting in an 18-fold increase (0·18 ± 0·04 vs 0·01 ± 0·007 apoptotic cells/mm growth plate, *P*<0·001) compared with controls.

**Caspase-3**

In control sections, caspase-3 immunoreactivity was localized in proliferative and early hypertrophic chondrocytes with no staining in mature and THCs. Dexamethasone treatment caused a significant increase in caspase-3 immunoreactivity in all layers of the growth plate and, more significantly, mature chondrocytes and THCs were also immunopositive (Fig. 1, Table 1).

**Bcl-2 and Bcl-x**

Immunoreactivity for the anti-apoptotic protein, Bcl-2, was localized throughout the growth plate in sections from control animals, although it was less abundant in mature and was almost absent in late/THCs (Fig. 1). Dexamethasone treatment caused a dramatic decrease in Bcl-2 immunoreactivity in all layers of the growth plate (Fig. 1, Table 1). Immunoreactivity for Bcl-x, another anti-apoptotic protein, was localized mainly in late proliferative and hypertrophic chondrocytes, especially at the interface between the proliferative and hypertropic zones (Fig. 1). Dexamethasone caused a significant decrease in Bcl-x immunoreactivity throughout the whole growth plate (Fig. 1, Table 1).

**PTHrP**

In control animals, PTHrP immunoreactivity was present in all layers of the growth plate but was more prominent in the hypertropic and resting zones (Fig. 1). Dexamethasone treatment caused a significant decrease in PTHrP immunoreactivity in all layers (Fig. 1, Table 1). Similar results were obtained with a second PTHrP antibody (mouse monoclonal antibody raised against amino acids 38–64 of human PTHrP; Oncogene Science).

**Discussion**

We report that dexamethasone treatment increases apoptosis in growth plate chondrocytes. The vast majority of the apoptotic cells were THCs and to a lesser extent early proliferative chondrocytes. In addition, increased apoptosis was associated with increased expression of caspase-3, and decreased expression of the anti-apoptotic proteins Bcl-2 and Bcl-x, which further support the activation of apoptotic signals in the growth plate after dexamethasone treatment.

Growth retardation after glucocorticoid treatment is characterized by decreased proliferation of the growth...
Apoptosis was observed mainly in terminal hypertropic chondrocytes (THCs) (with Alcian blue/van Gieson show the differences in the growth plate height in control (in the dexamethasone-treated group, whereas for Bcl-2, Bcl-x and PTHrP it was decreased. Microphotographs of growth plates stained magnification. The specificity of primary antibodies was assessed by replacement of primary antibodies with normal rabbit serum (f with preabsorption of the PTHrP antibody with blocking peptide (g).

Therefore, the combination of decreased proliferation and increased cell death could, together, explain glucocorticoid-induced growth retardation. Our data are further supported by a previously published study in older rats where increased apoptosis was observed after long treatment (3 weeks) with corticosterone (Silvestrini et al. 2000). Based on several observations we believe that the observed increased rate of apoptosis in the THCs reflects a real increase rather than an artifact. First, the immunoreactivity for caspase-3 was increased concomitantly with apoptosis and more specifically in the hypertropic and THCs where apoptosis was mainly observed. Secondly, both anti-apoptotic proteins, Bcl-2 and Bcl-x, were dramatically decreased in dexamethasone-treated rats. Finally, apoptosis was increased by dexamethasone not only in THCs but also in early proliferative chondrocytes although less frequently. The antibody for caspase-3 recognizes both proactive and active caspase-3 and therefore the immunoreactivity does not indicate which form is present. The several-fold increase in caspase-3 in the hypertropic chondrocytes where most apoptosis was observed, in association with the remarkable decrease in the anti-apoptotic proteins Bcl-2 and Bcl-x, could suggest an increase in the activation of the apoptotic pathway and therefore activation of caspases rather than an increase in the proactive caspase alone.

Decreased growth rate is associated with a longer lifespan of the growth plate chondrocytes (Huznirker et al. 1987). Therefore, one could argue that the observed increase in apoptosis after dexamethasone treatment is an artifact as the cells remain longer as THCs and thereby are more likely to be detected as apoptotic. We believe that this hypothesis is not valid because the final stage of apoptosis, as detected by TUNEL, is irreversible and there are no indications from the literature that this stage can be elongated. Moreover, our integrated data from caspase-3, Bcl-2, and Bcl-x clearly show that the growth plate is more susceptible to apoptosis after dexamethasone treatment.

**Table 1** Percentage (mean ± S.D.) of immunoreactive chondrocytes in the different zones in control and dexamethasone (Dexa)-treated rats

<table>
<thead>
<tr>
<th></th>
<th>Proliferative</th>
<th></th>
<th>Hypertrophic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Dexa</td>
<td>Control</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>45 ± 8</td>
<td>77 ± 11*</td>
<td>18 ± 2</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>78 ± 6</td>
<td>20 ± 0.1*</td>
<td>39 ± 5</td>
</tr>
<tr>
<td>Bcl-x</td>
<td>53 ± 2</td>
<td>10 ± 0.1*</td>
<td>81 ± 13</td>
</tr>
<tr>
<td>PTHrP</td>
<td>73 ± 9</td>
<td>32 ± 4*</td>
<td>94 ± 12</td>
</tr>
</tbody>
</table>

*p < 0.001 vs control.

![Figure 1](https://www.endocrinology.org) **Figure 1** Representative microphotographs of TUNEL assays from growth plates from control (a) and dexamethasone-treated (b, c) rats. Apoptosis was observed mainly in terminal hypertropic chondrocytes (THCs) (a, b) and dexamethasone caused a fourfold increase in apoptosis of THCs (b). Arrows indicate apoptotic chondrocytes in closed lacunae. Apoptotic proliferative chondrocytes were rare and an 18-fold increase was observed after dexamethasone (c). Bars represent 100 μm. Representative microphotographs of caspase-3, Bcl-2, Bcl-x and PTHrP immunohistochemistry from tibial growth plates in control and dexamethasone-treated rats are shown. Microphotographs from control sections have a magnification of 200×, whereas those from the dexamethasone-treated group have a magnification of 400× because the height of the growth plate is significantly smaller than that of controls. Immunoreactivity for caspase-3 was increased in the dexamethasone-treated group, whereas for Bcl-2, Bcl-x and PTHrP it was decreased. Microphotographs of growth plates stained with Alcian blue/van Gieson show the differences in the growth plate height in control (d) and dexamethasone (e) groups at 200× magnification. The specificity of primary antibodies was assessed by replacement of primary antibodies with normal rabbit serum (f) and with preabsorption of the PTHrP antibody with blocking peptide (g).
suggest an underlying mechanism for apoptosis induced by glucocorticoids which involves the PTHrP/Bcl-2 pathway. This is further supported by many in vitro studies in different cell lines, where dexamethasone downregulates the expression of parathyroid hormone (PTH)/PTHrP (Glatz et al. 1994, Southby et al. 1996).

Discontinuation of systemic glucocorticoid treatment in humans and mammals or treatment of Cushings syndrome in children leads to catch-up growth which is often incomplete and does not fully compensate for the growth deficit induced by glucocorticoid excess (Baron et al. 1994, Magiakou et al. 1994). We observed an increased number of apoptotic resting/early proliferative chondrocytes after dexamethasone treatment. Apoptotic resting/early proliferative chondrocytes were rare in occasional sections from control animals but after dexamethasone treatment an 18-fold increase was observed. It has been suggested that the observed catch-up growth after dexamethasone treatment is due to delayed senescence of the growth plate as the chondrocytes have undergone fewer replications due to the observed catch-up growth after dexamethasone treatment is associated with increased apoptosis induced by glucocorticoids which involves the PTHrP/Bcl-2 pathway. This is further supported by many in vitro studies in different cell lines, where dexamethasone downregulates the expression of parathyroid hormone (PTH)/PTHrP (Glatz et al. 1994, Southby et al. 1996).

In summary, we show that growth retardation after dexamethasone treatment is associated with increased apoptosis in the growth plate, which occurs through a down-regulation of the anti-apoptotic proteins Bcl-2 and Bcl-x and an increase in caspase-3. Our data support a model of glucocorticoid-induced apoptosis where the inhibition of the PTHrP expression causes a reduction of the anti-apoptotic protein Bcl-2 which triggers death signals in the growth plate chondrocytes. Finally, we propose that incomplete catch-up growth after prolonged exposure to supraphysiological concentrations of glucocorticoids could be secondary to premature loss of resting/proliferative chondrocytes by apoptosis.

**Acknowledgements**

This study was supported by the Swedish MRC (K2001-72X-13508-02B), the Karolinska Institute Research Foundation, the Cornell Foundation, the Sven Jerring Foundation, Wena Ekströms Stiftelsen, Erik Rönners Foundation, and Stiftelsen Frimurare Barnhuset in Stockholm.

**References**


Received 30 September 2002
Accepted 16 December 2002